Kaletra and Viread in Antiretroviral Naïve Patients
Status:
Terminated
Trial end date:
2011-05-01
Target enrollment:
Participant gender:
Summary
Once daily antiretroviral therapy with Viread (tenofovir DF, 300mg) plus Kaletra (LPV/r,
800mg/200mg) will be effective in suppressing and maintaining suppression of HIV RNA to <50
copies/ml in antiretroviral naïve patients through 48 weeks of therapy.
Phase:
Phase 4
Details
Lead Sponsor:
Oklahoma State University Center for Health Sciences